Dutch health fund projected to post €1.34bn deficit in 2026 after three surplus years

The Zorgverzekeringsfonds operating deficit returned in 2026 after three years of surpluses, reaching 1.34 billion euros even as the cumulative balance stayed slightly positive. This development occurred within the Zorgverzekeringswet framework, where the Zorgverzekeringsfonds serves as the central financing mechanism for Dutch statutory health insurance. Between 2006 and 2026 the fund saw total revenues and expenditures more than double while the insured population grew by only about one tenth.

Source: Zorginstituut Nederland, Publicatie Zvw 2006–2026 (Q1 2026 exploitation tables; amounts rounded from € million). Years 2006–2024 definitive; 2025–2026 as published.

Zorgverzekeringsfonds Operating Deficit and Cost Trends Through 2026

Risk-equalisation payments to insurers, the largest expenditure item, climbed from 14.4 billion euros in 2006 to 35.8 billion euros in 2026. Income-related contributions collected through the tax authority rose in tandem from 14.1 billion euros to 33.8 billion euros. The Zorgverzekeringsfonds operating deficit therefore reflects a structural gap that widened once the temporary COVID catastrophe scheme ended in 2023. Steady per-capita cost growth now drives the long-term trajectory rather than one-off events.

Ad

Financial Data Sources and Methodology

All figures derive from quarterly exploitation tables published by Zorginstituut Nederland and follow the transaction basis for recording claims. Data through 2024 are definitively established from the Financial Annual Report of the Funds, while 2025 and 2026 values remain provisional. The accounting framework isolates income-related contributions, state contributions for minors, and risk-equalisation payments from other revenue and expenditure streams. Zorginstituut Nederland continues to release these tables on a regular schedule to support transparency.

Fiscal Pressures and Market Access Implications

The sustained rise in risk-equalisation outflows relative to modest population growth points to tightening fiscal headroom inside the basic benefits package. Budget-impact assessments for new technologies must now account for the divergence between fund-level risk-equalisation flows and higher total expenditures recorded at insurer level. Continued monitoring of the cumulative operating balance will determine whether the current modest surplus can absorb future cost pressures without changes to contribution rates or entitlement criteria. The Zorgverzekeringsfonds operating deficit therefore serves as an early warning signal for policymakers evaluating long-term sustainability of the statutory system. Market access implications for high-cost drugs require ongoing scrutiny of Dutch Institute processes.